Group 1: Company Business Development - The company has established a comprehensive energy solution capability, driven by rapid expansion in the power equipment market, with increasing domestic and international project recognition [3] - The company is focusing on strategic customers to enhance business contributions, leveraging delivery, product performance, and product mix advantages [3] Group 2: SOFC Business Development - The company is committed to the SOFC sector, with a manufacturing license agreement signed with Xilis in November 2025 to establish production lines for fixed power generation [4] - Recent innovations have led to significant improvements in power generation efficiency and product performance, facilitating partnerships with leading domestic and international companies [4] Group 3: Heavy Truck Industry Trends - According to the China Association of Automobile Manufacturers, the heavy truck market is projected to sell 1.145 million units in 2025, a 27% year-on-year increase, with exports reaching 341,000 units, up 17.4% [5] - The company is optimistic about the heavy truck industry's future, planning to enhance its product matrix and accelerate new energy layouts to meet diverse customer needs [5] Group 4: Shareholder Returns Outlook - The company aims to optimize profit structure and enhance long-term competitiveness while maintaining a high cash dividend and share buyback policy to improve shareholder returns [6] - Future shareholder return policies will consider various stakeholder expectations and market conditions, ensuring a proactive and stable approach [6]

Group 1: Company Development and Financial Performance - The company has maintained steady growth since its listing in October 2010, with net profits increasing from over 30 million RMB to more than 190 million RMB by 2021, despite a slight decline projected for 2022-2024, with a minimum profit of over 147 million RMB [1] - The company focuses on rare earth permanent magnets, with investments in projects like samarium-cobalt magnets and magnetic powders, which have low costs and risks but slow returns [1] Group 2: Acquisition Plans and Strategic Rationale - The acquisition of Kyoto Longtai is aimed at expanding the company's product range and meeting existing customer demands for ferrite materials, which are cost-effective and widely used [1] - The target company has established competitive advantages in the ferrite sector, making it a strategic fit for the company's growth [1] Group 3: Business Growth and Market Trends - The company’s existing business is experiencing growth, particularly in bonded magnets, with a positive trend in demand driven by automation and smart technology [2] - The company’s magnetic powder business has improved in performance, stability, and cost-effectiveness through recent R&D efforts, contributing to net profit [2] Group 4: Future Business Plans and Market Considerations - Currently, the company has no new business plans and is focused on optimizing existing operations [2] - The company acknowledges that fluctuations in rare earth prices and government policies can impact operations, but overall demand for electric motors is expected to rise, benefiting the company [2] Group 5: Investment Considerations and Risks - The investment in the target company is seen as high-risk with potentially low short-term returns, but future business developments could improve investment returns [2] - Establishing a new company would require significant time and resources for customer development and team formation, whereas the target company already has an established customer base and management team [2]

Group 1: Product Development and Clinical Research - The pharmaceutical division is focusing on the secondary development of key products, including clinical studies on Yunnan Baiyao (powder and capsules) for diabetic foot and bone pain, and Gongxue Ning capsules for treating abnormal uterine bleeding [2][3] - Recent clinical research results show Gongxue Ning capsules effectively reduce post-abortion vaginal bleeding and complications, with good overall safety [3] - The Qi Xue Kang oral solution is undergoing multi-center clinical studies for hypertension, with the first patient enrolled successfully [3] Group 2: Business Strategy and Market Expansion - The provincial pharmaceutical company aims to enhance market share in existing hospitals and distribution channels through a "double rise and double drop" strategy, focusing on non-drug businesses and new specialty pharmacies [4] - Efforts will be made to optimize supply chain management and improve accounts receivable and inventory structure, aiming for a patient-centered healthcare ecosystem [4] Group 3: Online Sales Performance - The pharmaceutical division's O2O sales increased by over 20% in the first half of 2025, with significant online marketing efforts boosting product awareness and sales [6] - During the 2025 "618" shopping festival, Yunnan Baiyao toothpaste ranked first in the domestic market share across all channels [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7][8] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, amounting to 1.82 billion CNY, with special dividends accounting for 50.05% of the net profit for that period [8]

Group 1: Online Expansion of Pharmaceutical Business - The pharmaceutical business group has integrated marketing strategies focusing on sports, music, and O2O transaction scenarios, enhancing brand engagement and sales [2] - O2O sales have increased by over 20% year-on-year, supported by online content marketing [2] - The online sales achieved significant results, with e-commerce platforms attracting 48.45 million visitors, generating a GMV of 254 million yuan [3] Group 2: Health Products Sales Performance - The Yangyuanqing hair care products generated sales revenue of 217 million yuan in the first half of 2025, reflecting an 11% year-on-year growth [4] - Yangyuanqing won the "ICIC Technology Innovation Hair Care Product Award" and ranked first in Tmall's domestic anti-hair loss shampoo category during the 2025 "618" shopping festival [4] Group 3: Research and Development Progress - The clinical trials for the product "All Sanqi Tablets" have completed Phase II with 704 participants [5] - The "Fuguben Ointment" has initiated Phase III clinical trials across 15 research centers, enrolling 180 participants [5] - The INR101 diagnostic nuclear medicine project has started Phase III trials with 32 research centers, enrolling 60 participants [5] Group 4: Dividend Distribution - In 2024, the company will distribute a cash dividend of 11.85 yuan per 10 shares, totaling 2.16 billion yuan, which is 90.09% of the net profit attributable to shareholders [6][7] - For the first half of 2025, a cash dividend of 10.19 yuan per 10 shares will be distributed, amounting to 1.82 billion yuan, with special dividends accounting for 50.05% of the net profit for the same period [7]

编号：3-2601-03 云南白药集团股份有限公司 投资者调研会议记录表 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 国泰海通-张澄 东证资管-马庆华 时间 2026 年 1 月 22 日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 22 日星期四 1 / 1 ...

Group 1: Marketing Strategies - The pharmaceutical business unit focuses on becoming the "first brand" in the field of injury and pain management, leading to significant growth in aerosol and plaster products [2] - A comprehensive marketing strategy integrates various scenarios such as sports and music, utilizing platforms like Douyin and Xiaohongshu for broad dissemination [3] - Online sales through O2O channels increased by over 20%, with a total of 48.45 million visitors and 3.54 million consumers generated, resulting in a GMV of 254 million yuan [3] Group 2: R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [4] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with 12 patients enrolled in the Phase I trial [4] Group 3: Health Products Sales - The health products business unit maintains a strong offline presence while increasing investment in online channels, achieving the top market share for toothpaste in China during the first half of 2025 [6] - During the 2025 "618" shopping festival, Yangyuanqing ranked first in Tmall for domestic anti-hair loss shampoo brands [6] Group 4: Development Directions - The company aims for "internal" and "external" collaborative development to optimize its industrial portfolio, focusing on enhancing efficiency in the pharmaceutical, health, and distribution sectors [7] - "Internal" development emphasizes maximizing overall efficiency and high-quality growth across the entire value chain, while "external" development explores strategic mergers and collaborations to overcome growth bottlenecks [7]

投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 国泰海通-张澄 人保资产-黄海培、吴瑞祥、章斌、武丹 时间 2026 年 1 月 22 日 地点 集团总部办公大楼 上市公司接待人员 董事会秘书-钱映辉 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 22 日星期四 编号：2-2601-02 云南白药集团股份有限公司 投资者调研会议记录表 1 / 1 ...

投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 华西医药-程仲瑶 易方达-郭杰、余欣鑫、廖敏华、邓子晗、胡可冕 时间 2026 年 1 月 21 日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 21 日星期三 1 / 1 投资者调研会议记录表 编号：1-2601-01 云南白药集团股份有限公司 ...

Group 1: Company Overview and Market Position - Sichuan Zhongguang Lightning Protection Technology Co., Ltd. is a leading enterprise in the lightning protection sector in China, supplying products to major global communication equipment manufacturers such as Ericsson, ZTE, Nokia, and Samsung [2]. - The company reported a revenue of CNY 111.23 million in the communication sector for the first half of 2025, marking a year-on-year growth of 12.43% [2]. - The company holds a unique position in the market, being the only publicly listed company in the Shanghai and Shenzhen stock exchanges with over 50% of its main business revenue derived from lightning protection [4]. Group 2: Product Development and Revenue Growth - The company's electronic components, including magnetic components and RF devices, achieved a revenue of CNY 57.31 million in the first half of 2025, reflecting a significant year-on-year increase of 70.73% [2]. - In the energy sector, the company reported a revenue of CNY 82.35 million in the first half of 2025, which is a 35.84% increase compared to the previous year, driven by rising customer demand [3]. Group 3: Technological Advancements and R&D - The company has developed EMP protection products capable of shielding against nuclear electromagnetic pulses and high-power microwave radiation, although these products have not yet reached mass production [3]. - The company is actively involved in the development of 6G technology, maintaining close technical ties with clients and adapting to their customized product needs [3]. Group 4: Industry Applications and Projects - The company has participated in numerous lightning protection engineering projects, including those for high-speed rail, nuclear power plants, and military applications, covering complex scenarios such as the Qinghai-Tibet Railway and the CCTV headquarters [3]. - In the renewable energy sector, the company provides tailored SPD products for traditional power, wind, solar energy, and charging stations, enhancing its market share through innovative product offerings [3].

Group 1: Semiconductor Sector Development - The company is focusing on the domestic semiconductor equipment localization, achieving a revenue of CNY 26,712.22 million in the semiconductor sector, a year-on-year increase of 48.67% [1][2] - The core products in the semiconductor field, including thickness measurement products, OCD equipment, and electron beam equipment, are leading in the domestic industry [2] - Advanced process products have become the main revenue driver, with an increasing proportion in overall revenue and orders [2] Group 2: Display Detection Sector Progress - The flat panel display industry is recovering, with expected investments in large and ultra-large LCDs; OLED technology is maturing, leading to increased application and sales [3] - In Q3 2025, the display segment achieved sales revenue of CNY 56,474.58 million, a 14.67% increase year-on-year, with a net profit of CNY 12,147 million [3] Group 3: Subsidiary Development - Wuhan Jinghong focuses on automatic test equipment (ATE) for semiconductor testing, covering the entire testing process from wafer probing to final testing [4][5] - An investment of CNY 4,000 million was made to enhance Wuhan Jinghong's R&D and production capabilities [5] Group 4: Advanced Packaging Technology - The company is strategically investing in advanced packaging technology by acquiring a 33.6414% stake in Hubei Xingchen, enhancing collaboration with key clients [5] - Hubei Xingchen has established a leading 12-inch integrated circuit advanced packaging R&D line, currently in the customer introduction phase [5] Group 5: Land Acquisition for Expansion - Shanghai Jingce plans to purchase land use rights for a new laboratory expansion project with a total investment of approximately CNY 350 million [6] - This project aims to enhance R&D capabilities and alleviate current production line resource constraints, supporting future business growth [6][7]